Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Comment by savannahssavvyon Jun 16, 2010 4:32pm
358 Views
Post# 17195333

RE: RE: Buy Out

RE: RE: Buy Out"Covidien could look to exit the deal to save the development costs for Pennsaid Plus."

How might Covidien achieve this end, Consultant99? Was the agreement between NUVO and Covidien concerning Pennsaid Plus (now known as Pennsaid Gel) not signed, sealed and delivered?

Apropos, perhaps, a NR appeared this morning indicating that Somanetics shareholders are less than pleased with the low-ball offer from Covidien currently on their table:

"Holzer Holzer & Fistel, LLC Announces Investigation into the Proposed Buyout of Somanetics by Covidien plc (bwire)

ATLANTA (Business Wire) -- Holzer Holzer & Fistel, LLC is investigating whether the directors of Somanetics Corporation (“Somanetics” or the “Company”) (NASDAQ: SMTS) complied with their fiduciary duties in approving the proposed buyout of the Company by Covidien plc (NYSE: COV). According to the terms of the agreement, Somanetics shareholders would receive $25.00 per share if the deal is approved. The investigation seeks to determine if the consideration to be paid to Somanetics shareholders is fair and adequate.

Current holders of Somanetics common stock with questions concerning their legal rights are encouraged to contact Holzer Holzer & Fistel, LLC and its attorneys Michael I. Fistel, Jr., Esq. or Marshall P. Dees, Esq. via email at mfistel@holzerlaw.com or mdees@holzerlaw.com, or via toll-free telephone at (888) 508-6832.

Holzer Holzer & Fistel, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content."

As an aside, thank you for keeping your wardrobe woes to yourself LOL
Bullboard Posts